These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 21838869)
21. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Agouridis AP; Tsimihodimos V; Filippatos TD; Tselepis AD; Elisaf MS Lipids; 2011 Jun; 46(6):521-8. PubMed ID: 21327725 [TBL] [Abstract][Full Text] [Related]
23. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα. Ducheix S; Podechard N; Lasserre F; Polizzi A; Pommier A; Murzilli S; Di Lisio C; D'Amore S; Bertrand-Michel J; Montagner A; Pineau T; Loiseau N; Lobaccaro JM; Martin PG; Guillou H Biochimie; 2013 Mar; 95(3):556-67. PubMed ID: 23063693 [TBL] [Abstract][Full Text] [Related]
24. The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis. Dias PCS; Sena-Evangelista KCM; Paiva MSMO; Ferreira DQC; Ururahy MAG; Rezende AA; Abdalla DSP; Pedrosa LFC J Trace Elem Med Biol; 2014 Apr; 28(2):194-199. PubMed ID: 24560278 [TBL] [Abstract][Full Text] [Related]
25. Editorial: Treatment of atherosclerosis as an inflammatory disease. Tuttolomondo A Curr Pharm Des; 2012; 18(28):4265. PubMed ID: 22857131 [No Abstract] [Full Text] [Related]
26. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585 [TBL] [Abstract][Full Text] [Related]
27. Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. Kostapanos MS; Rizos CV; Elisaf MS Drug Saf; 2014 Jul; 37(7):481-500. PubMed ID: 24788803 [TBL] [Abstract][Full Text] [Related]
28. Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels. Šilhavý J; Zídek V; Landa V; Šimáková M; Mlejnek P; Škop V; Oliyarnyk O; Kazdová L; Mancini M; Saar K; Schulz H; Hübner N; Kurtz TW; Pravenec M Cardiovasc Ther; 2014 Apr; 32(2):59-65. PubMed ID: 24410968 [TBL] [Abstract][Full Text] [Related]
29. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665 [TBL] [Abstract][Full Text] [Related]
30. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. Chen J; Li D; Schaefer RF; Mehta JL J Cardiovasc Pharmacol; 2004 Oct; 44(4):446-52. PubMed ID: 15454852 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of notch enhances the anti-atherosclerotic effects of LXR agonists while reducing fatty liver development in ApoE-deficient mice. Hao Y; Wang X; Zhang F; Wang M; Wang Y; Wang H; Du Y; Wang T; Fu F; Gao Z; Zhang L Toxicol Appl Pharmacol; 2020 Nov; 406():115211. PubMed ID: 32853627 [TBL] [Abstract][Full Text] [Related]
32. Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia. Kei A; Liberopoulos EN; Mikhailidis DP; Elisaf M Int J Clin Pract; 2013 May; 67(5):412-9. PubMed ID: 23510018 [TBL] [Abstract][Full Text] [Related]
33. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607 [TBL] [Abstract][Full Text] [Related]
34. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896 [TBL] [Abstract][Full Text] [Related]
35. The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease. Fessler MB Pharmacol Ther; 2018 Jan; 181():1-12. PubMed ID: 28720427 [TBL] [Abstract][Full Text] [Related]
36. Stabilizing the vulnerable plaque: the search for the magic bullet. Pasterkamp G; Daemen M Curr Pharm Des; 2007; 13(10):979-82. PubMed ID: 17430161 [No Abstract] [Full Text] [Related]
37. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Kostapanos MS; Milionis HJ; Elisaf MS Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931 [TBL] [Abstract][Full Text] [Related]
38. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Stalker TJ; Lefer AM; Scalia R Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257 [TBL] [Abstract][Full Text] [Related]
39. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Nicholls SJ; Borgman M; Nissen SE; Raichlen JS; Ballantyne C; Barter P; Chapman MJ; Erbel R; Libby P Curr Med Res Opin; 2011 Jun; 27(6):1119-29. PubMed ID: 21446892 [TBL] [Abstract][Full Text] [Related]
40. [Efficacy of lipid correcting therapy with the use of rosuvastatin]. Ivleva AIa Kardiologiia; 2005; 45(6):71-80. PubMed ID: 16007037 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]